精美幻灯(2010美国临床肿瘤学会年会恶性血液病最新进展) PPT课件.ppt

June 4-8, 2010Chicago, Illinois
Hematologic O Independent Conference Coverageof the 2010 American Society of Clinical Oncology Annual Meeting*
*CCO is an independent medical pany that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
This program is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene, Genentech BioOncology, Millennium Pharmaceuticals, Inc., Novartis Oncology, and Pfizer, Inc.
About These Slides
Our thanks to the presenters who gave permission to include their original data
Users are encouraged to use these slides in their own mercial presentations, but we ask that content and attribution not be changed. Users are asked to honor this intent
These slides may not be published or posted online without permission from Clinical Care Options (email permissions@)
DisclaimerThe materials published on the Clinical Care Options Web site reflect the views of the authors of the CCO material, not those of Clinical Care Options, LLC, the CME providers, or panies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Faculty
Nicholas J. DiBella, MDCo-Chairman, Hematology mittee, US Oncology President, Rocky Mountain Cancer Centers Aurora, Colorado
An Update on Hematologic Malignancies: Overview
PRIMA: rituximab maintenance vs observation in patients with follicular lymphoma who responded to induction with rituximab plus chemotherapy
Phase II trial of panobinostat in relapsed/refractory Hodgkin’s lymphoma
Phase II trial of R-GemOx for patients with relapsed/refractory DLBCL not candidates for high-do